



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 487/18, 519/00, 471/04, A61K 31/47, 31/435, 31/445	A1	(11) International Publication Number: WO 94/15938 (43) International Publication Date: 21 July 1994 (21.07.94)
---	----	--

(21) International Application Number: PCT/KR94/00005

(22) International Filing Date: 18 January 1994 (18.01.94)

(30) Priority Data:
1993/543 18 January 1993 (18.01.93) KR

(71) Applicants (for all designated States except US): KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY [KR/KR]; 100, Jang-dong, Yuseong-ku, Daejeon 305-606 (KR). SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KIM, Wan, Joo [KR/KR]; 387-7, Doryong-dong, Yuseong-ku, Daejeon 305-606 (KR). PARK, Tae, Ho [KR/KR]; Hyundai Apartment 101-302, 431-6, Doryong-dong, Yuseong-ku, Daejeon 305-606 (KR). KIM, Bong, Jin [KR/KR]; Hanwool Apartment 101-903, Sinsung-dong, Yuseong-ku, Daejeon 305-345 (KR). KIM, Moon, Hwan [KR/KR]; Hanbit Apartment 138-1203, 99, Ayeun-dong, Yuseong-ku, Daejeon 305-333 (KR). PEARSON, Neil [GB/GB]; Brockham Park, Betchworth, Surrey RH3 7AJ (GB).


(74) Agent: LEE, Kuiy, Dong; Seoul Building, 114-31, Uni-dong, Chongro-ku, Seoul 110-350 (KR).

(81) Designated States: AU, CA, CN, JP, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).


Published

With international search report.


(54) Title: NOVEL QUINOLONE DERIVATIVES AND PROCESSES FOR PREPARING THE SAME



(I)



(III)



(IV)

(57) Abstract

The present invention relates to novel quinolone derivatives of formulae (I), (III) and (IV) having a broad antibacterial spectrum and to processes for preparing the same: wherein X₁ represents hydrogen, amino group, chloro, fluoro, or methyl; X₂ represents hydrogen or halogen; Y₁ and Y₂ each represent hydrogen, or lower alkyl (C₁₋₃) group; R₁ represents ethyl, cyclopropyl, halogen(F, Cl)-substituted cyclopropyl or halogen-substituted phenyl; R₂ represents hydrogen, methyl, ethyl or *t*-butoxycarbonyl; R₃ and R₄ each represent hydrogen, nitro group, methoxycarbonyl group, ethoxycarbonyl group or nitril group; and A represents nitrogen atom, methyn group, fluoromethyn group, chloromethyn group, methoxymethyn group, or methylmethyn group.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

Novel Quinolone Derivatives and Processes for Preparing the Same

5

Technical Field

The present invention relates to novel quinolone derivatives which have a broad
10 antibacterial spectrum, and processes for preparing the same.

Background Art

Nalidixic acid developed in 1963 is the first one of quinolonecarboxylic acid-type
15 antibacterials. Quinolonecarboxylic acid-type antibacterials are known to exhibit
strong antibacterial activity against aerobic *Gram-negative* bacteria and have been
effectively used as a treatment for urethritis. Among these quinolone carboxylic acid-
type antibacterials, especially norfloxacin, ciprofloxacin, ofloxacin, etc. are clinically
used. However, these prior art compounds suffer from the disadvantage that they
20 have drastically inferior antibacterial activity against *Gram-positive* bacteria, while
they have superior antibacterial activity against *Gram-negative* bacteria. Especially,
these quinolone-type antibacterials are known to have weak antibacterial activity
against *Gram-positive* bacteria such as *Staphylococcus* or *Enterococcus* which show
high resistance to sepeem-type or β -lactam-type antibacterial agents.

25

Disclosure of Invention


The present invention provides novel quinolone derivatives of formula (I), (III)
and (IV) below and processes for preparing the same.

30


- 2 -

5

10



15



20

25 wherein,

X_1 represents hydrogen, amino group, halogen such as chloro, fluoro, or lower alkyl such as methyl;

X_2 represents hydrogen or halogen;

Y_1 and Y_2 each represents hydrogen, or lower alkyl (C_{1-3}) group;

30 R_1 represents a straight chain or cyclic lower alkyl group having 1 to 3 carbon atoms or a straight chain or cyclic lower alkyl group having 1 to 3 carbon atoms which is substituted with a halogen atom, a phenyl group or a phenyl group substituted with one or two halogen atoms;

R_2 represents hydrogen, or lower alkyl such as methyl, ethyl;

35 R_3 and R_4 each represent hydrogen, nitro group, methoxycarbonyl group,

- 3 -

ethoxycarbonyl group or nitril group; and

A represents nitrogen atom or $-C=$,



5 in which Y represents hydrogen, halogen, lower alkyl or alkoxy or together with R_1 forms $-\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)-$, $-\text{OCH}_2\text{CH}_2-$, $-\text{OCH}_2\text{CH}(\text{CH}_3)-$, $-\text{SCH}_2\text{CH}_2-$, or $-\text{SCH}_2\text{CH}(\text{CH}_3)-$.

10 A is preferably nitrogen, methyn, fluoromethyn, chloromethyn, methoxymethyn, or methylmethyn.

Lower alkyl is preferably C_{1-6} alkyl, more preferably C_{1-4} alkyl, such as methyl or ethyl. X_2 halogen is preferably fluorine.


R_1 is preferably ethyl, cyclopropyl, halogen (F, Cl)-substituted cyclopropyl or halogen substituted phenyl.

15

The present invention is described in detail hereinbelow.

20 The present invention provides novel quinolone carboxylic acid derivatives of formula (I), and specifically, to novel quinolone carboxylic acid derivatives of formula (I) below which have trans-2,8-diazabicyclo[4.3.0]nonane derivatives represented by the formula (II) at 7-position of quinolone nucleus and possess a broad spectrum of potent antibacterial activities, and to processes for preparing the same.

25



30

wherein,

X_1 , X_2 , Y_1 , Y_2 , R_1 , R_2 , and A are the same as defined above.



35

- 4 -

The present invention also provides novel quinolone carboxylic acid derivatives represented by the formula (III) and (IV) including mixtures thereof which show a broad spectrum of potent antibacterial activities, and to processes for preparing the same.

5

10



15


wherein,

20 X_1 , X_2 , Y_1 , Y_2 , R_1 , R_2 , R_3 , R_4 , and A are the same as defined above.

The present invention provides trans-2,8-diazabicyclo[4.3.0]nonane derivatives represented by the formula (II) which are used as a side chain at 7-position of novel quinolone carboxylic acid derivatives (I) and processes for preparing the same.

25

30




wherein,

35 Y_1 , Y_2 , and R_2 are the same as defined above.

- 4 -

The present invention also provides novel quinolone carboxylic acid derivatives represented by the formula (III) and (IV) including mixtures thereof which show a broad spectrum of potent antibacterial activities, and to processes for preparing the same.

5



15

wherein,

20 X_1 , X_2 , Y_1 , Y_2 , R_1 , R_2 , R_3 , R_4 , and A are the same as defined above.

The present invention provides trans-2,8-diazabicyclo[4.3.0]nonane derivatives represented by the formula (II) which are used as a side chain at 7-position of novel quinolone carboxylic acid derivatives (I) and processes for preparing the same.

25




30

wherein,

35 Y_1 , Y_2 , and R_2 are the same as defined above.

- 5 -

The present invention also provides novel processes for preparing *cis*-2,8-diazabicyclo[4.3.0]nonane derivatives represented by the following formula (V) which are used as a side chain at 7-position of formula (IV) above.




wherein,

Y_1 and R_2 are the same as defined above.

15 Quinolone derivatives of formula (I) according to the present invention may be prepared by condensing optionally protected *trans*-2,8-diazabicyclo [4.3.0]nonane derivatives of formula (II) above with the known compound of formula (VI-1) (P.D.Fernandes, "International Telesymposium on Quinolone", J.R.Prous Science, Barcelona, Spain, 1989. 1-143) in a solvent, in the presence of an inorganic or
20 organic base, as described in the process (A). Inorganic bases used in this process include potassium carbonate and the like. Organic base used herein include diazabicyclo[5.4.0]undecene (DBU), pyridine, triethylamine and the like. The above reaction may be carried out at a temperature between room temperature and 150°C. The reaction time is about 1 to 10 hours.

25 Process (A)



35

- 6 -

wherein,


X_1 , X_2 , Y_1 , Y_2 , R_1 , R_2 , and A are the same as defined above or R_2 is a protecting group such as *t*-butoxy carbonyl which is removed subsequently.

- 5 Also, quinolone derivatives represented by formula (III) of the present invention may be prepared by the following process (B). That is, the compound of formula (III) can be prepared by stirring compound of formula (I) and an activating agent such as carbodiimidazole (CDI) under reflux in the presence of a solvent such as chloroform, tetrahydrofuran (THF) and the like and then stirring nitromethane, diethylmalonate, dimethylmalonate, ethylnitrylacetate under reflux together with solution treated with
10 a base such as sodium hydride, calcium carbonate, sodium carbonate in the presence of a solvent such as THF, and the like.

Process (B)

15

20



25


wherein,

X_1 , X_2 , Y_1 , Y_2 , R_1 , R_2 , R_3 , and R_4 are the same as defined above; and represent nitro group, nitryl group, diethoxycarbonyl group, or dimethoxycarbonyl group, and thereafter optionally interconverting R_3 and R_4 .

30

Quinolone derivatives represented by formula (IV) of the present invention may be prepared by the following process (C). That is, the compound of formula (IV) can be prepared by reacting optionally protected *cis*-2,8-diazabicyclo[4.3.0]nonane derivatives of formula (V) with the compound of formula (IV-2) under reflux stirring in a solvent of acetonitrile or dimethylformamide (DMF) in the presence of basic,
35 neutral, or acidic alumina.

- 7 -

Process (C)

wherein,

X_1 , X_2 , Y_1 , R_1 , R_2 , R_3 , and A are the same as defined above or R_2 is a protecting group such as *t*-butoxy carbonyl which is removed subsequently.

15

Novel quinolone derivatives of formula (IV) above can be also prepared by stirring the condensed compound with the solution under reflux. The condensed compound may be prepared by reacting *cis*-2,8-diazabicyclo[4.3.0]nonane derivatives of formula (V) with the known compound of formula (VI-2) in a solvent in the presence of an organic or inorganic base. Organic base used herein include diazabicyclo[5.4.0]undecene(DBU), pyridine, triethylamine and the like. Inorganic bases used in this process include potassium carbonate and the like. The above reaction may be carried out at a temperature between room temperature and 150°C. The reaction time is about 1 to 10 hours. The above solution is prepared by stirring carbodiimidazole under reflux in a solvent such as chloroform, tetrahydrofuran, and then stirring nitromethane, diethylmalonate, dimethylmalonate, ethylnitrylacetate under reflux with a base such as sodium hydride, calcium carbonate, sodium carbonate in a solvent such as tetrahydrofuran and the like.

30

The compounds of formula (I), (III) and (IV) above can be converted to the pharmaceutically acceptable salts thereof according to the conventional method. For example, these compounds can be converted to salts of inorganic acid such as hydrochloric acid, sulfuric acid, and phosphoric acid or salts of organic acid such as methansulfonic acid, lactic acid, oxalic acid, and acetic acid.

35

- 8 -

Trans-2,8-diazabicyclo[4.3.0]nonane derivatives of the following formula (II) according to the present invention can be prepared by the following Process (D). The Process(D) comprises the following four steps:

5 Step (1):

The compound of formula (VIII) can be prepared by reacting the known compound of formula (VII) (J.Org.Chem. 48, 1129 (1983)) with β -alanine derivatives in the presence of ethanol under reflux;

10

Step (2):

The compound of formula (IX) can be prepared by cyclizing the compound of formula (VIII) with alkoxide such as sodium ethoxide or potassium *t*-butoxide at room temperature in the aromatic solvent such as benzene, toluene;

15

Step (3):


The compound of formula (X) can be prepared by reacting the carbonyl compound of formula (IX) with tosylhydrazine in a solvent of ethanol or methanol to obtain tosylhydrazone and then, by reducing the resulting compound with sodium shanobrohydride; and

20

Step (4):

25

The compound of formula (II) can be prepared by debenzylating the compound of formula (X) in methanol solvent in the presence of a catalyst of palladium or platinum.

Process (D)

wherein,

Y_1 , Y_2 , and R_2 are the same as defined above.

20 *Trans*-2,8-diazabicyclo[4.3.0]nonane derivatives of the following formula (II) according to the present invention can also be prepared by the following Process (E). The Process(E) comprises the following seven steps:

Step (5):

25

Trans isomer of formula (XIII) can be prepared by reacting the known compound of formula (XII) (UK Patent No. 1,086,637, or Chemical Abstract, 68, 96695W) with β -alanine derivatives in the presence of ethanol under reflux;

30 Step (6):

Cis isomer of formula (XIV) can be prepared by reacting *trans* isomer of formula (XIII) with methansulfonyl chloride or lithium chloride, in methylene chloride or chloroform, in the presence of an organic base such as triethylamine or diisopropylethylamine, at the temperature between 0°C and 60°C;

35

- 10 -

Step (7):

Trans isomer of formula (XV) can be prepared by reacting *cis* isomer of formula (XIV) with potassium cyanate or sodium cyanate in DMF solvent;

5

Steps (8) and (9):

The compound of formula (IX) can be prepared from the compound of formula (XV) by the same method as Step (2) of Process (D) above;

10

Step (10):

The compound of formula (X) can be prepared by reducing the compound of formula (IX) with zinc amalgam in the presence of hydrochloric acid; and


15

Step (11):

The compound of formula (II) can be prepared from the compound of formula (X) by the same method as Step (4) of Process (D) above.

20

- 11 -

Process (E)

wherein,

 Y_1 , Y_2 and R_2 are the same as defined above.

30 *Cis*-2,8-diazabicyclo[4.3.0]nonane derivatives of the formula (V) according to the present invention can be prepared by the following Process (F). The Process(D) comprises the following seven steps:

Step (12):

35 The ester compound of formula (XVIII) can be prepared by suspending

- 12 -

conventional pyridine derivatives of formula (XVII) in methanol and adding thionylchloride thereto and then stirring the resulting compound under reflux;

Step (13):

5

Alcohols of formula (XIX) can be prepared by reducing the compound of formula (XVIII) with lithium aluminum hydride in ethylether or THF;

Step (14):

10

The compound of formula (XX) can be prepared by chlorinating, brominating, or methane sulfonylating alcohols of formula (XIX);

Step (15):

15

The cyclized compound of formula (XXI) can be prepared by reacting the compound of formula (XX) with tosylimide and sodiumhydride in DMF;

Step (16):

20

Amines of formula (XXII) can be prepared by hydrolyzing the compound of formula (XXI) with 48% of hydrobromic acid;

Step (17):

25

Salts of pyridine of formula (XXIII) can be prepared by reacting amine compounds of formula (XXII) with methaneiodide and acid anhydrous in a solvent of methylene chloride or ethyl alcohol; and


Step (18):

30

Cis-2,8-diazabicyclo[4.3.0]nonane derivatives of formula (V) can be prepared by hydrogenating the compound of formula (XXIII) in a solvent of methanol or ethanol in the presence of a catalyst of palladium or platinum.

35

- 13 -

Process (F)

30 The following examples are intended to further illustrate the present invention, without limiting the scope of the invention.

Example 1: Preparation of trans-piperidinopyrrolidine

35 1) Preparation according to Process (D)

- 14 -

i) Preparation of *trans*-1-benzyl-3-carboethoxy-4-[N-benzyl-N-(2-carboethoxy)ethyl]aminopyrrolidine

5 A mixture of 23.9g of 1-benzyl-3-ethoxycarbonyl-3-pyrroline and 19.2g of β -N-benzylalanine ethylester were added to 100ml of ethanol and stirred under reflux for 3 days. The solvent was evaporated under reduced pressure and then the residual product was purified by a silica gel column chromatography (nucleic acid-ethylacetate (3:1)) to give 26.9g of the above title compound (yield: 65%).

10 $^1\text{H-NMR}(\text{CDCl}_3, \delta)$: 2.21(2H, m), 2.51(2H, m), 3.10-4.01(6H, m), 3.71(6H, s), 7.25(10H, m)

ii) Preparation of *trans*-N,N'-dibenzyl-2,8-diazabicyclo[4.3.0]-5-oxononane

15 20.5g of *trans*-1-benzyl-3-carboethoxy-4-[N-benzyl-N(2carboethoxy)ethyl]aminopyrrolidine was dissolved in 200ml of toluene and the reaction mixture was cooled in ice bath and then 6.1g of potassium *t*-butoxide was added dropwise thereto. After adding dropwise, the reaction mixture was heated to 40°C and stirred for 4 hours. The reaction mixture was evaporated under reduced pressure and the
20 residue was dissolved in water. The resulting product was neutralized with aqueous solution of sodium bicarbonate, extracted with ethylacetate and then dried with anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure and then the residual product was purified by a silica gel column chromatography to give 11.8g of the above title compound (yield: 71%).

25 $^1\text{H-NMR}(\text{CDCl}_3, \delta)$: 2.30-3.0(9H, m), 3.20-3.70(2H, q), 3.50(6H, s), 3.4(1H, q), 7.15(10H, m)

iii) Preparation of *trans*-N,N'-dibenzylpiperidinopyrrolidine

30 15.9g of *trans*-N,N'-dibenzyl-2,8-diazabicyclo[4.3.0]-5-oxononane and 9.3g of tosyl hydrazine was added to 100ml of ethanol and then dehydrated with Dean-Stark distillation apparatus. 14g of sodium borohydride was added thereto and the mixture was stirred for 4 hours. The solvent was evaporated under reduced pressure
35 and then the residue was extracted with ethylether. The mixture of ethylether was

- 15 -

evaporated under reduced pressure and then the residual product was purified by a silica gel column chromatography (nucleic acid-ethylacetate (3:1)) to give 13.2g of the above title compound (yield: 87%).

5 ¹H-NMR(CDCl₃, δ): 1.54-2.01(5H, m), 2.74-3.10(7H, m), 3.20-3.70(4H, m)
7.30(10H, m)

iv) Preparation of *trans*-piperidinopyrrolidine dihydrochloride

10 13.15g of *trans*-N,N'-dibenzylpiperidinopyrrolidine were dissolved in 50ml of methanol and then 1.0g of 10% Pd/C and 60ml of 30% methanol were added thereto. The resulting solution was hydrogenated by Parr hydrogenation reactor and debenzylated. The reaction mixture was filtered through celite and the filtrate was evaporated under reduced pressure. The residue was dissolved in 10ml of methanol
15 and ethylether was added dropwise to the mixture. The resulting mixture was solidified and filtered to give 7.43g of the above title compound (yield: 93%).

¹H-NMR(CDCl₃, δ): 1.50-1.90(5H, m), 2.74-3.01(7H, m)

20 2) Preparation according to Process (E)

i) Preparation of *trans*-1-benzyl-3-hydroxy-4-[N-benzyl-N-(2-carboethoxy)ethyl]aminopyrrolidine

25 87.25g (0.5 mol) of 3-benzyl-6-oxy-3-azabicyclo[3.1.0]nucleic acid and 113.8g (0.51 mol) of 3N-benzylaminopropanoate were put into 200ml of pyridine and stirred under reflux for 3 days. The reaction mixture was evaporated under reduced pressure to remove pyridine and then the residue was subjected to a silica gel column chromatography (nucleic acid-ethylacetate (1:1)) to give 166.2g of the above title
30 compound (yield: 87%).

¹H-NMR(CDCl₃, δ): 1.26(3H, t), 2.24(2H, m), 2.50(2H, m), 3.90(1H, m),
3.10-4.0(9H, m), 4.20(2H, q), 7.23(10H, m)

35 ii) Preparation of *cis*-1-benzyl-3-chloro-4-[N-benzyl-N-(2-carboethoxy)ethyl]

- 16 -

aminopyrrolidine

95.5g (0.25 mol) of *trans*-1-benzyl-3-hydroxy-4-[N-benzyl-N-(2-carboethoxy)ethyl]aminopyrrolidine and 70ml of triethylamine were dissolved in 1l of methylene chloride and 31.4g of methane sulfonyl chloride were added dropwise thereto at 0°C. 21.3g of anhydrous lithium chloride were added to the mixture and the reaction mixture was heated to 60°C and stirred for 20 hours. The reaction mixture was cooled, washed with water and dried over anhydrous magnesium sulfate. After the solvent was evaporated under reduced pressure, the residue was purified by a silica gel column chromatography (nucleic acid-ethylacetate (3:1)) to give 80.15g of the above title compound (yield: 82%).

¹H-NMR(CDCl₃, δ): 1.26(3H, t), 2.24-2.52(4H, m), 3.10-4.0(9H, m), 4.14(1H, m), 4.20(2H, q), 7.30(10H, m)

15

iii) Preparation of *trans*-1-benzyl-3-cyano-4-[N-benzyl-N-(2-carboethoxy)ethyl]aminopyrrolidine

40.1g (0.1 mol) of *trans*-1-benzyl-3-chloro-4-[N-benzyl-N-(2-carboethoxy)ethyl]aminopyrrolidine and 7.8g of potassium cyanate were put into 100ml of DMF and the mixture was heated at 60°C for 14 hours while stirring. The reaction mixture was added to 400ml of ice water while stirring and the produced solid was filtered. The resulting solid was dissolved in ethylacetate and then the mixture was subjected to a silica gel column chromatography (nucleic acid-ethylacetate (3:1)) to give 30.5g of the desired compound (yield: 78%).

25

¹H-NMR(CDCl₃, δ): 1.27(3H, t), 2.24(2H, m), 2.50(2H, m), 3.10-4.0(9H, m), 4.20(2H, q), 7.30(10H, m)

iv) Preparation of *trans*-1-benzyl-3-carboethoxy-4-[N-benzyl-N-(2-carboethoxy)ethyl]aminopyrrolidine

30.0g of *trans*-1-benzyl-3-cyano-4-[N-benzyl-N-(2-carboethoxy)ethyl]aminopyrrolidine were put into 300ml of 10% hydrochloric acid and the mixture was refluxed for 6 hours. After water was evaporated under reduced pressure, the residue

35

- 17 -

was heated and dried in vacuum drier for 10 hours. The residue was suspended in 200ml of methanol and 30ml of thionylchloride was added dropwise to the mixture while refluxing and further refluxed for 5 hours. The reaction mixture was evaporated under reduced pressure, the residue was put into methanol and 11g of sodium methoxide was added gradually thereto at 0°C. The resulting mixture was evaporated under reduced pressure again, dissolved in ethylacetate and washed with water. The organic layer was dried over anhydrous magnesium sulfate and evaporated under reduced pressure, and the residue was subjected to a silica gel column chromatography (nucleic acid-ethylacetate (3:1)) to give 30.5g of the title compound (yield: 61%).

¹H-NMR(CDCl₃, δ): 2.21(2H, m), 2.51(2H, m), 3.10-4.01(6H, m), 3.71(6H, s), 7.25(10H, m)

15

v) Preparation of *trans*-N,N'-dibenzyl-2,8-diazabicyclo[4.3.0]-5-oxononane

20.5g of *trans*-1-benzyl-3-carboethoxy-4-[N-benzyl-N-(carboethoxy)ethyl] aminopyrrolidine was dissolved in 200ml of toluene and the reaction mixture was cooled in ice bath and then 6.1g of potassium *t*-butoxide was added dropwise thereto. After adding dropwise, the reaction mixture was heated to 40°C and stirred for 4 hours. The reaction mixture was evaporated under reduced pressure and the residue was dissolved in water. The resulting product was neutralized with aqueous solution of sodium bicarbonate, extracted with ethylacetate and then dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure and then the residual product was purified by a silica gel column chromatography to give 11.8g of the above title compound (yield: 74%).

¹H-NMR(CDCl₃, δ): 2.30-3.0(9H, m), 3.20-3.70(2H, q), 3.50(6H, s), 3.4(1H, q), 7.15(10H, m)

vi) Preparation of *trans*-N,N'-dibenzyl-piperidinopyrrolidine

6.5g of zinc powder were put into 15ml of aqueous solution of 5% HgCl₂ and the mixture solution was shaken for 1 hour. The supernatant was removed and 9.6g

- 18 -

of N,N'-dibenzyl-2,8-diazabicyclo[4.3.0]-5-oxononane was added thereto. 10ml of 15% hydrochloric acid was added and the solution was heated while refluxing for 6 hours. While refluxing, 10ml of 5% hydrochloric acid was added several times. The mixture was cooled and 40ml of ethylacetate was added thereto and then supernatant
5 of the mixture was removed. The suspension was filtered and the filtrate was neutralized with 5% KOH and extracted with ethylacetate. The extracted solution was dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure and then the residual product was purified by a silica gel column chromatography (nucleic acid-ethylacetate (3:1)) to give 7.44g of the above title
10 compound (yield: 81%).

¹H-NMR(CDCl₃, δ): 1.54-2.01(5H, m), 2.74-3.10(7H, m), 3.2-3.70(4H, m),
7.30(10H, m)

15 vii) Preparation of *trans*-piperidinopyrrolidine dihydrochloride

6.12g (0.02 mol) of *trans*-N,N'-dibenzyl-piperidinopyrrolidine were dissolved in 30ml of methanol and then 0.5g of 10% Pd/C and 5ml of fumaric acid were added thereto. The resulting solution was hydrogenated by Parr hydrogenation reactor
20 (initial hydrogen pressure: 60psi) to debenzylate. The reaction mixture was filtered through celite and the filtrate was evaporated under reduced pressure. The residue was dissolved in 10ml of 30% hydrochloride methanol and ethylether was added dropwise to the mixture. The resulting mixture was solidified and filtered to give 3.62g of the above title compound (yield: 92%).

25

¹H-NMR(CDCl₃, δ): 1.50-1.90(5H, m), 2.74-3.01(7H, m)

30 Example 2: Preparation of *trans*-3-methyl-piperidinopyrrolidine dihydrochloride

According to the same method as i), ii), iii), iv), v), vi) and vii) of Process (E) in Example 1, 121g of methyl-3-(N-benzyl)aminobutanoate as a starting material was used to give 22.9g of the above title compound (total yield: 10.1%).

35 ¹H-NMR(CDCl₃, δ): 1.42-1.90(7H, m), 2.74-3.01(7H, m)

- 19 -

Example 3: Preparation of *cis*-piperidinopyrrolidine dihydrobromide**1) Preparation of 2,3-dimethoxycarbonylpyridine**

5

26.7g of 2,3-pyridinedicarboxylic acid were put into 500ml of methanol saturated with hydrogen chloride and the mixture was refluxed for 10 hours. Methanol was evaporated under reduced pressure and then the residual product was purified by a silica gel column chromatography (nucleic acid-ethylacetate (1:1)) to give 25.1g of the above pure title compound (yield: 85%).

10

¹H-NMR(CDCl₃, δ): 3.95(6H, s), 7.34(1H, m), 7.51(1H, d), 8.84(1H, d)

2) Preparation of 2,3-dihydroxymethylpyridine

15

A solution prepared by dissolving 29.5g of 2,3-dimethoxycarbonylpyridine in 200ml of ethylether was added dropwise to a solution prepared by suspending 10g of lithium aluminum hydride in 300ml of dried ethylether at 0°C. This mixed solution was stirred at 20°C for 3 hours and 30ml of water was slowly added thereto at 0°C. The resulting solution was stirred for 5 hours at the room temperature and solid was filtered through celite. The filtrate was evaporated under reduced pressure and then the residual product was purified by a silica gel column chromatography (chloroform : methanol (10:1)) to give 10.4g of the above title compound (yield: 75%).

20

¹H-NMR(CDCl₃ + DMSO-d₆, δ): 4.58(2H, d), 4.67(2H, d), 5.13(1H, s), 5.30(1H, s), 7.34(1H, m), 7.45(1H, d), 8.45(1H, d)

25

3) Preparation of 2,3-dichloromethylpyridine hydrochloride

30

13.9 g of 2,3-dihydroxymethylpyridine and thionylchloride were evaporated under reduced pressure to give 21.2g of the above title compound in yellow solid (yield: 99%).

- 20 -

¹H-NMR(CDCl₃ + DMSO-d₆, δ): 5.10(2H, s), 5.15(2H, s), 7.81(1H, m),
8.15(1H, m), 8.15(1H, d), 8.95(1H, d)

4) Preparation of 2,3-dihydro-2-*p*-toluene sulfonyl-1H-pyrrolo[2.3.c]pyridine

5
A solution prepared by suspending 0.9g of 60% sodiumhydride in 50ml of dried dimethylformamide was slowly added dropwise over 2 hours to a solution prepared by dissolving 3.5g of *p*-toluenephosphenylamide in 20ml of dried dimethylformamide. The reacting mixture was stirred for 1 hour at the room
10 temperature and then stirred again for 1 hour at the temperature between 65 and 70°C. A solution prepared by dissolving 2.13g of 2,3-dichloromethylpyridine in 3ml of dried dimethylformamide was added to the reaction mixture. The resulting mixture was stirred for 3 hours at the same temperature and 20ml of water was added thereto. The solvent was evaporated off under reduced pressure. 20ml of water was added
15 again to the mixture, and the resulting mixture was saturated with sodium hydroxide and extracted with 100ml of ethylacetate. The extracted solution was dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure and then the residual product was purified by a silica gel column chromatography (nucleic acid-ethylacetate (1:2)) to give 1.8g of the above title compound (yield:
20 65%).

¹H-NMR(CDCl₃, δ): 2.45(3H, s), 4.65-4.68(4H, d), 7.15(1H, m), 7.35(3H, d, d),
7.81(2H, m), 8.46(1H, d)

25 5) Preparation of 2,3-dihydro-1H-pyrrolo[2.3.c]pyridine dihydrobromide

74g of 2,3-dihydro-2-*p*-toluene sulfonyl-1H-pyrrolo[2.3.c.]pyridine was put into 20ml of 48% hydrobromide, and 1.75g of phenol and 9.18ml of propionic acid was added thereto and then the reaction mixture was refluxed for 48
30 hours. The reaction mixture was evaporated under reduced pressure and 30ml of water was added to. The water layer was washed with ethylacetate and then water soluble layer was concentrated and stood in a refrigerator to give 2.23g of the above title compound (yield: 79%).

35 ¹H-NMR(DMSO-d₆, δ): 5.24(4H, δ), 7.85(1H, m), 8.20(1H, d), 8.90(1H, d)

- 21 -

6) Preparation of *cis*-piperidinopyrrolidine dihydrobromide

1.42g of 2,3-dihydro-1H-pyrrolo[2.3.c]pyridine hydrobromide was dissolved in 30ml of methanol and the mixture was suspended with 1g of 10% Pd/C. The resulting solution was hydrogenated by Parr hydrogenation reactor (initial hydrogen pressure: 60psi) to debenzylate. After the reaction was finished, the reaction solution was filtered through celite and the solvent was evaporated *in vacuo* to give 1.42g of the above title compound (yield: 99%).

10

¹H-NMR(DMSO-d₆, δ): 1.51-1.94(5H, m), 2.71-3.12(7H, m)

Example 4: Preparation of *cis*-3-methyl-piperidinopyrrolidine dihydrobromide

15

According to the same method as i), ii), iii), iv), v) and vi) of Example 3, 28.1g of 5-methyl-2,3-dicarboxypyridine was used to give 8.88g of the above title compound (total yield: 30%).

¹H-NMR(DMSO-d₆, δ): 1.2(4H, m), 1.50-1.91(5H, m), 2.74-3.01(7H, m), 4.10(1H, m), 7.7(1H, dxd), 8.6(1H, s)

Example 5: Preparation of 1-cyclopropyl-6-fluoro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-8-chloro-1,4-dihydroquinoline-4-oxo-3-carboxylic acid

25

300mg of 1-cyclopropyl-6,7-difluoro-1,4-dihydroquinoline-4-oxo-3-carboxylic acid and 210mg of *trans*-piperidinopyrrolidine dihydrochloride were suspended in 10ml of anhydrous acetonitrile and 0.18ml of DBU was added thereto. The reaction mixture was refluxed for 6 hours and cooled to the room temperature. The produced solid was filtered and washed with acetonitrile to give 405.5mg of the above title compound (yield: 100%).

¹H-NMR(DMSO-d₆, δ): 1.22(4H, m), 1.61-2.01(5H, m), 2.74-3.01(7H, m), 4.08(1H, m), 7.56(1H, dxd), 8.61(1H, s)

35

- 22 -

Example 6: Preparation of 1-cyclopropyl-6,8-difluoro-7-[(trans-piperidinopyrrolidine)-8-yl]-1,4-dihydroquinoline-4-oxo-3-carboxylic acid

5

283mg of 1-cyclopropyl-6,7,8-trifluoro-1,4-dihydroquinoline-4-oxo-3-carboxylic acid and 210mg of *trans*-piperidinopyrrolidine dihydrochloride were treated according to the same method as that of Example 5 to give 327mg of the
10 above title compound (yield: 84%).

¹H-NMR(DMSO-d₆, δ): 1.2(4H, m), 1.50-1.91(5H, m), 2.74-3.01(7H, m),
4.10(1H, m), 7.7(1H, dxd), 8.6(1H, s)

15

Following compounds may be prepared by the process similar to that described in Example 5.

1-cyclopropyl-6-fluoro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-1,4-dihydroquinoline-4-oxo-3-carboxylic acid;
20

1-cyclopropyl-5-amino-6,8-difluoro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-1,4-dihydroquinoline-4-oxo-3-carboxylic acid;

25 1-cyclopropyl-5-methyl-6-fluoro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-1,4-dihydroquinoline-4-oxo-3-carboxylic acid;

1-cyclopropyl-6-fluoro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-8-methoxy-1,4-dihydroquinoline-4-oxo-3-carboxylic acid;
30

1-cyclopropyl-6-fluoro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-1,4-dihydro-4-oxo-1,8-naphthyridin-3-carboxylic acid;

- 23 -

1-(2,4-difluorophenyl)-6-fluoro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-1,4-dihydro-4-oxo-1,8-naphthyridin-3-carboxylic acid;

5 9-fluoro-10-[(*trans*-piperidinopyrrolidine)-8-yl]-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de][1,4]-benzooxazine-6-carboxylic acid;

1-cyclopropyl-6,8-difluoro-7-[(3-methyl-2,8-diazabicyclo[4.3.0]nonane)-8-yl]-1,4-dihydroquinoline-4-oxo-3-carboxylic acid;

10 1-cyclopropyl-6-fluoro-7-[(*trans*-3-methyl-2,8-diazabicyclo[4.3.0]nonane)-8-yl]-8-chloro-1,4-dihydroquinoline-4-oxo-3-carboxylic acid;

1-cyclopropyl-5-amino-6,8-difluoro-7-[(*trans*-3-methyl-2,8-diazabicyclo[4.3.0]nonane)-8-yl]-1,4-dihydroquinoline-4-oxo-3-carboxylic acid;

15

1-cyclopropyl-5-methyl-6-fluoro-7-[(*trans*-3-methyl-2,8-diazabicyclo[4.3.0]nonane)-8-yl]-1,4-dihydroquinoline-4-oxo-3-carboxylic acid;

20 1-cyclopropyl-6-fluoro-7-[(*trans*-3-methyl-2,8-diazabicyclo[4.3.0]nonane)-8-yl]-8-methoxy-1,4-dihydroquinoline-4-oxo-3-carboxylic acid;

1-cyclopropyl-6-fluoro-7-[(*trans*-3-methyl-2,8-diazabicyclo[4.3.0]nonane)-8-yl]-1,4-dihydro-4-oxo-1,8-naphthyridin-3-carboxylic acid; and

25 9-fluoro-10-[(*trans*-3-methyl-2,8-diazabicyclo[4.3.0]nonane)-8-yl]-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de][1,4]-benzooxazine-6-carboxylic acid.

30 Example 7: Preparation of 1-cyclopropyl-3-nitroacetyl-6-fluoro-8-chloro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-4-oxo-1,4-dihydroquinoline hydrochloride

183mg of nitromethane was dissolved in 10ml of tetrahydrofuran and 120mg of 60% NaH was suspended in the mixture. The resulting solution was stirred for
35 3 hours at 40°C. 403.5mg of 1-cyclopropyl-6-fluoro-8-chloro-7-[(*trans*-2-(N-*t*-

- 24 -

butoxycarbonyl)piperidinopyrrolidine)-8-yl]-oxo-1,4-dihydroquinoline-3-carboxylic acid, 324mg of CDI and 10ml of chloroform were put into the above solution. The resulting solution was stirred under reflux for 12 hours and the solvent was evaporated under reduced pressure. The produced residue was added to 10ml of THF and the mixture was stirred under reflux for 4 hours. The reaction solvent was evaporated under reduced pressure and the residue was suspended in 20ml of water. The suspension was neutralized with acetic acid and extracted with ethylacetate (20ml x 3). The extracted solution was dried over anhydrous magnesium sulfate and the solvent was evaporated under reduced pressure. The produced residue was purified by column chromatography (CHCl_3 : MeOH = 9 : 1) to give 389mg of 1-cyclopropyl-3-nitroacetyl-6-fluoro-8-chloro-7-[(*trans*-2-(*N*-*t*-butoxycarbonyl)piperidinopyrrolidine)-8-yl]-4-oxo-1,4-dihydroquinoline. This compound was put into 5ml of 10% methanol solution of hydrogen chloride and the mixture was stirred for 4 hours at room temperature and then 5ml of ethylether was added thereto. The produced solid was filtered and dried under reduced pressure to give 335mg of the above title compound (yield: 64%).

$^1\text{H-NMR}(\text{DMSO-}d_6, \delta)$: 1.22(4H, m), 1.01-1.98(5H, m), 2.78-3.08(7H, m), 4.06(1H, m), 6.18(2H, s), 7.74(1H, dxd), 8.78(1H, s)

Example 8: Preparation of 1-cyclopropyl-3-nitroacetyl-6-fluoro-8-methoxy-7-[(*trans*-piperidinopyrrolidine)-8-yl]-4-oxo-1,4-dihydroquinoline hydrochloride

497mg of 1-cyclopropyl-6-fluoro-8-methoxy-7-[(*trans*-2-(*N*-*t*-butoxycarbonyl)piperidinopyrrolidine)-8-yl]-oxo-1,4-dihydroquinoline-3-carboxylic acid were treated according to the same method as that of Example 7 to give 327mg of the title compound (yield: 74%).

$^1\text{H-NMR}(\text{DMSO-}d_6, \delta)$: 1.20(4H, m), 1.51-1.91(5H, m), 2.70-3.04(7H, m), 3.86(3H, s), 4.00(1H, m), 6.16(2H, s), 7.86(1H, d), 8.84(1H, s)

Following compounds may be prepared by the process similar to that described in Example 7.

- 25 -

1-cyclopropyl-3-nitroacetyl-6,8-difluoro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-4-oxo-1,4-dihydroquinoline hydrochloride;

5 1-cyclopropyl-3-nitroacetyl-5-amino-6,8-difluoro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-4-oxo-1,4-dihydroquinoline hydrochloride;

1-(2,4-difluoro)phenyl-3-nitroacetyl-6-fluoro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-4-oxo-1,4-dihydro-1,8-naphthyridine hydrochloride;

10 1-cyclopropyl-3-nitroacetyl-6,8-difluoro-7-[(*trans*-2,8-diazabicyclo[4.3.0]nonane-3-methyl)-8-yl]-4-oxo-1,4-dihydroquinoline hydrochloride; and

1-cyclopropyl-3-(diethoxycarbonyl)acetyl-6,8-difluoro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-4-oxo-1,4-dihydroquinoline hydrochloride.

15

1-cyclopropyl-3-(dimethoxycarbonyl)acetyl-6-fluoro-8-methoxy-7-[(*trans*-piperidinopyrrolidine)-8-yl]-4-oxo-1,4-dihydroquinoline hydrochloride.

20

Example 9: Preparation of 1-cyclopropyl-3-nitroacetyl-6-fluoro-8-methoxy-7-[(*cis*-piperidinopyrrolidine)-8-yl]-4-oxo-1,4-dihydroquinoline hydrochloride

1) Preparation according to Process (B)

25

497mg of 1-cyclopropyl-6-fluoro-8-methoxy-7-[(*cis*-2-(*N*-*t*-butoxycarbonyl)piperidinopyrrolidine)-8-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid were treated according to the same method as that of Example 7 to give 314mg of the above title compound (yield: 71%).

30

¹H-NMR(DMSO-d₆, δ): 1.18(4H, m), 1.57-2.00(5H, m), 2.70-3.04(7H, m), 3.86(3H, s), 4.00(1H, m), 6.18(2H, s), 7.86(1H, d), 8.84(1H, s)

2) Preparation according to Process (C)

35

- 26 -

i) Preparation of 1-cyclopropyl-3-nitroacetyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydroquinoline

566mg of 1-cyclopropyl-6,7,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and 648mg of CDI were put into 20ml of THF and the mixture solution is stirred under reflux for 24 hours (A solution). 366mg of nitromethane was mixed in 5ml of THF and 240mg of 60% NaH added thereto. The mixture solution was stirred for 24 hours at room temperature and the above A solution was added thereto. The resulting solution was stirred under reflux for 14 hours. The reaction mixture was cooled and the solvent was evaporated under reduced pressure. The produced residue was purified by column chromatography (nucleic acid : ethylacetate = 5 : 1) to give 450mg of the above title compound (yield: 69%).

¹H-NMR(DMSO-d₆, δ): 1.20(4H, m), 3.62(3H, s), 4.00(1H, m), 6.12(2H, s), 7.67(1H, d), 8.60(1H, s)

ii) Preparation of 1-cyclopropyl-3-nitroacetyl-6-fluoro-8-methoxy-7-[(*cis*-piperidinopyrrolidine)-8-yl]-4-oxo-1,4-dihydroquinolinehydrochloride

338mg of 1-cyclopropyl-3-nitroacetyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydroquinoline and 310mg of *cis*-piperidinopyrrolidine were dissolved in 10ml of acetonitrile. 310mg of alumina were added thereto and the mixture was stirred for 10 hours at 60°C. The reaction mixture was evaporated under reduced pressure and the produced residue was suspended in methanol and the mixture solution was stirred under reflux and filtered. The filtrate was collected and evaporated under reduced pressure. The produced residue was put into 15ml of 10% solution of HCl-methanol and the mixture solution was stirred for 2 hours at room temperature. 15ml of ethylether was added thereto and the resulting solution was filtered to give 296mg of the above title compound (yield: 67%).

¹H-NMR(DMSO-d₆, δ): 1.18(4H, m), 1.57-2.00(5H, m), 2.70-3.04(7H, m), 3.86(3H, s), 4.00(1H, m), 6.18(2H, s), 7.86(1H, d), 8.84(1H, s)

35

- 27 -

Following compounds may be prepared by the process similar to that described in Example 9.

1-cyclopropyl-3-(diethoxycarbonyl)acetyl-6-fluoro-8-chloro-7-[(*cis*-piperidinopyrrolidine)-8-yl]-4-oxo-1,4-dihydroquinoline hydrochlorid e;

1-cyclopropyl-3-nitroacetyl-6,8-difluoro-7-[(*cis*-2,8-diazabicyclo[4.3.0]nonane-3-methyl)-8-yl]-4-oxo-1,4-dihydroquinoline hydrochloride; and

1-cyclopropyl-3-(dimethoxycarbonyl)acetyl-6-fluoro-8-methoxy-7-[(*cis*-piperidinopyrrolidine)-8-yl]-4-oxo-1,4-dihydroquinoline hydrochloride.

Comparative Example 1: Preparation of 1-cyclopropyl-6-fluoro-8-methoxy-7-[(*cis*-piperidinopyrrolidine)-8-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

295mg of 1-cyclopropyl-6,7-difluoro-8-methoxy-1,4-dihydro-4-oxo-3-carboxylic acid and 210mg of *cis*-piperidinopyrrolidine dihydrochloride were treated according to the same method as that of Example 5 to give 324mg of the above title compound (yield: 81%).

¹H-NMR(CDCl₃, δ): 1.14-1.22(4H, m), 1.51-1.91(5H, m), 2.71-2.98(7H, m), 3.82(3H, s), 4.00(1H, m), 7.84(1H, d), 8.80(1H, s)

Comparative Example 2: Preparation of 1-cyclopropyl-6,8-difluoro-7-[(*cis*-piperidinopyrrolidine-3-methyl)-8-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

283mg of 1-cyclopropyl-6,7,8-trifluoro-1,4-dihydroquinoline-4-oxo-3-carboxylic acid and 232mg of *cis*-3-methylpiperidinopyrrolidine dihydrochloride were treated according to the same method as that of Example 5 to give 280mg of the above title compound (yield: 71%).

¹H-NMR(CDCl₃, δ): 1.20(4H, m), 1.56-1.92(8H, m), 2.70-3.00(6H, m), 4.00(1H, m), 7.72(1H, d), 8.68(1H, s)

- 28 -

In vitro antibacterial activity test

- 5 The results of *in vitro* antibacterial activity test are shown in Tables 1 and 2. The numbers in Tables represent the minimal inhibitory concentration (MIC, $\mu\text{g/ml}$) of the corresponding strains and MIC was determined in accordance with the agar culture medium two-fold dilution method by using a Mueller-Hinton agar.
- 10 Hoechst standard strains were used. The strains having 10^7 CFU/ml were inoculated on the culture medium, and the growth of the strains was observed after incubating them at 37°C for 18 hours, in which ciprofloxacin was used as a control.

- 29 -

Table 1: *In vitro* antibacterial activity test (MIC, ug/ml)


5	Strain	A	B	C	D	Ciprofloxacin
	<i>Streptococcus pyogenes</i> 308A	0.391	0.781	0.781	1.563	3.125
	<i>Streptococcus pyogenes</i> 77A	0.098	0.195	0.391	0.391	0.781
	<i>Streptococcus faecium</i> MD 8b	0.098	0.195	0.391	0.391	0.781
10	<i>Staphylococcus aureus</i> SG 511	0.025	0.098	0.098	0.195	0.195
	<i>Staphylococcus aureus</i> 285	0.025	0.098	0.025	0.391	0.391
	<i>Staphylococcus aureus</i> 503	0.025	0.195	0.025	0.391	0.781
	<i>Escherichia coli</i> O 78	<0.002	<0.025	<0.002	0.049	<0.002
	<i>Escherichia coli</i> DC 0	0.195	0.391	0.195	0.195	0.195
15	<i>Escherichia coli</i> DC 2	0.013	0.098	0.098	0.098	0.098
	<i>Escherichia coli</i> TEM	0.007	0.049	0.004	0.098	0.007
	<i>Escherichia coli</i> 1507E	0.025	0.049	0.025	0.098	0.007
	<i>Pseudomonas aeruginosa</i> 9027	0.781	0.781	0.781	1.563	0.391
	<i>Pseudomonas aeruginosa</i> 1592E	0.781	0.781	0.781	0.781	0.195
20	<i>Pseudomonas aeruginosa</i> 1771	0.781	1.563	0.781	0.781	0.195
	<i>Pseudomonas aeruginosa</i> 1771M	0.195	0.391	0.391	0.391	0.049
	<i>Salmonella typhimurium</i>	<0.002	0.049	0.007	0.098	0.007
	<i>Klebsiella aerogenes</i> 1082E	<0.002	0.098	0.049	0.049	<0.002
	<i>Klebsiella aerogenes</i> 1552E	0.049	0.098	0.013	0.049	0.013
25	<i>Enterobacter cloacae</i> P 99	0.004	0.025	0.004	0.013	0.007
	<i>Enterobacter cloacae</i> 1321E	<0.002	0.013	<0.002	0.013	<0.002

- 30
- A: The compound of Example 5
 B: The compound of Example 7
 C: The compound of Example 8
 D: The compound of Example 9

- 30 -

What is claimed is:

1. Novel quinolone derivatives of Formula (I):



wherein,

X₁ represents hydrogen, amino, halogen, or lower alkyl;

X₂ represents hydrogen or halogen;

Y₁ and Y₂ each represents hydrogen, or lower alkyl (C₁₋₃) group;

15 R₁ represents a straight chain or cyclic lower alkyl group having 1 to 3 carbon atoms or a straight chain or cyclic lower alkyl group having 1 to 3 carbon atoms which is substituted with a halogen atom, a phenyl group or a phenyl group substituted with one or two halogen atoms;

R₂ represents hydrogen, or lower alkyl; and

20 A represents nitrogen atom or -C=,



in which Y represents hydrogen, halogen, lower alkyl or alkoxy or together with R₁ forms -CH₂CH₂CH₂-, -CH₂CH₂CH(CH₃)-, -OCH₂CH₂-, -OCH₂CH(CH₃)-, -SCH₂CH₂-,
25 , or -SCH₂CH(CH₃)-.

2. Compounds of Claim 1 wherein the compounds of Formula (I) is one of the following compounds;

30

1-cyclopropyl-6-fluoro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-8-chloro-1,4-dihydroquinoline-4-oxo-3-carboxylic acid,

1-cyclopropyl-6,8-difluoro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-1,4-dihydroquinoline-
35 4-oxo-3-carboxylic acid,

- 31 -


- 1-cyclopropyl-6-fluoro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-1,4-dihydroquinoline-4-oxo-3-carboxylic acid,
- 5 1-cyclopropyl-5-amino-6,8-difluoro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-1,4-dihydroquinoline-4-oxo-3-carboxylic acid,
- 1-cyclopropyl-5-methyl-6-fluoro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-1,4-dihydroquinoline-4-oxo-3-carboxylic acid,
- 10 1-cyclopropyl-6-fluoro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-8-methoxy-1,4-dihydroquinoline-4-oxo-3-carboxylic acid,
- 1-cyclopropyl-6-fluoro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-1,4-dihydro-4-oxo-1,8-naphthyridin-3-carboxylic acid,
- 15 1-(2,4-difluorophenyl)-6-fluoro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-1,4-dihydro-4-oxo-1,8-naphthyridin-3-carboxylic acid,
- 9-fluoro-10-[(*trans*-piperidinopyrrolidine)-8-yl]-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de][1,4]-benzooxazine-6-carboxylic acid,
- 20 1-cyclopropyl-6,8-difluoro-7-[(*trans*-3-methyl-2,8-diazabicyclo[4.3.0]nonane)-8-yl]-1,4-dihydroquinoline-4-oxo-3-carboxylic acid,
- 25 1-cyclopropyl-6-fluoro-7-[(*trans*-3-methyl-2,8-diazabicyclo[4.3.0]nonane)-8-yl]-8-chloro-1,4-dihydroquinoline-4-oxo-3-carboxylic acid,
- 1-cyclopropyl-5-amino-6,8-difluoro-7-[(*trans*-3-methyl-2,8-diazabicyclo[4.3.0]nonane)-8-yl]-1,4-dihydroquinoline-4-oxo-3-carboxylic acid,
- 30 1-cyclopropyl-5-methyl-6-fluoro-7-[(*trans*-3-methyl-2,8-diazabicyclo[4.3.0]nonane)-8-yl]-1,4-dihydroquinoline-4-oxo-3-carboxylic acid,
- 1-cyclopropyl-6-fluoro-7-[(*trans*-3-methyl-2,8-diazabicyclo[4.3.0]nonane)-8-yl]-8-methoxy-1,4-dihydroquinoline-4-oxo-3-carboxylic acid,
- 35

- 32 -

1-cyclopropyl-6-fluoro-7-[(*trans*-3-methyl-2,8-diazabicyclo[4.3.0]nonane)-8-yl]-1,4-dihydro-4-oxo-1,8-naphthyridin-3-carboxylic acid,

9-fluoro-10-[(*trans*-3-methyl-2,8-diazabicyclo[4.3.0]nonane)-8-yl]-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de][1,4]-benzoxazine-6-carboxylic acid.


3. A process for preparing compounds of Formula (I) comprising condensing optionally protected *trans*-2,8-diazabicyclo [4.3.0]nonane derivatives of formula (II) with the compound of formula (VI-1) in a solvent, in the presence of an inorganic base such as calcium carbonate and the like or an organic base such as diazabicyclo[5.4.0]undecene (DBU), pyridine, triethylamine and the like:



wherein,

X_1 , X_2 , Y_1 , Y_2 , R_1 , R_2 , and A are the same as defined in Claim 1 or R_2 is a protecting group, and thereafter optionally deprotecting.

4. Novel quinolone derivatives of Formula (III):



- 33 -

wherein,

X₁, X₂, Y₁, Y₂, R₁, R₂, and A are the same as defined in Claim 1; and

R₃, and R₄ each represents hydrogen, nitro group, nitril group, methoxycarbonyl group, or ethoxycarbonyl group.

5

5. Compounds of Claim 4 wherein the compounds of Formula (III) is one of the following compounds;

1-cyclopropyl-3-nitroacetyl-6-fluoro-8-chloro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-4-
10 oxo-1,4-dihydroquinoline hydrochloride,

1-cyclopropyl-3-nitroacetyl-6-fluoro-8-methoxy-7-[(*trans*-piperidinopyrrolidine)-8-yl]-
4-oxo-1,4-dihydroquinoline hydrochloride,

15 1-cyclopropyl-3-nitroacetyl-6,8-difluoro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-4-oxo-
1,4-dihydroquinoline hydrochloride,

1-cyclopropyl-3-nitroacetyl-5-amino-6,8-difluoro-7-[(*trans*-piperidinopyrrolidine)-8-
yl]-4-oxo-1,4-dihydroquinoline hydrochloride,

20

1-(2,4-difluoro)phenyl-3-nitroacetyl-6-fluoro-7-[(*trans*-piperidinopyrrolidine)-8-yl]-4-
oxo-1,4-dihydro-1,8-naphthyridine hydrochloride,

1-cyclopropyl-3-nitroacetyl-6,8-difluoro-7-[(*trans*-2,8-diazabicyclo[4.3.0]nonane-3-
25 methyl)-8-yl]-4-oxo-1,4-dihydroquinoline hydrochloride,

1-cyclopropyl-3-(diethoxycarbonyl)acetyl-6,8-difluoro-7-[(*trans*-piperidinopyrrolidine)-
8-yl]-4-oxo-1,4-dihydroquinoline hydrochloride,


30 1-cyclopropyl-3-(dimethoxycarbonyl)acetyl-6-fluoro-8-methoxy-7-[(*trans*-
piperidinopyrrolidine)-8-yl]-4-oxo-1,4-dihydroquinoline hydrochloride.

6. A process for preparing compounds of Formula (III) comprising reacting
compound of formula (I) with an activating agent such as carbodiimidazole (CDI) in
35 the presence of a solvent such as chloroform, tetrahydrofuran (THF) and the like; and

- 34 -

then stirring together with solution prepared by treating nitromethane, diethylmalonate, dimethylmalonate, ethylnitrylacetate with a base such as sodium hydride, calcium carbonate, sodium carbonate in the presence of a solvent such as tetrahydrofuran, and the like:

5




15 wherein,

X₁, X₂, Y₁, Y₂, R₁, R₂, R₃, R₄, and A are the same as defined in Claim 3 and thereafter optionally interconverting R₃ and R₄.

7. Novel quinolone derivatives of Formula (IV):

20



25

30 wherein,

X₁, X₂, Y₁, R₁, R₂, R₃, R₄ and A are the same as defined in Claim 3.

8. Compounds of Claim 7 wherein the compounds of Formula (IV) is one of the following compounds;

35

- 35 -


1-cyclopropyl-3-nitroacetyl-6-fluoro-8-methoxy-7-[(*cis*-piperidinopyrrolidine)-8-yl]-4-oxo-1,4-dihydroquinoline hydrochloride,

1-cyclopropyl-3-(diethoxycarbonyl)acetyl-6-fluoro-8-chloro-7-[(*cis*-piperidinopyrrolidine)-8-yl]-4-oxo-1,4-dihydroquinoline hydrochloride,

1-cyclopropyl-3-nitroacetyl-6,8-difluoro-7-[(*cis*-2,8-diazabicyclo[4.3.0]nonane-3-methyl)-8-yl]-4-oxo-1,4-dihydroquinoline hydrochloride,

1-cyclopropyl-3-(dimethoxycarbonyl)acetyl-6-fluoro-8-methoxy-7-[(*cis*-piperidinopyrrolidine)-8-yl]-4-oxo-1,4-dihydroquinoline hydrochloride.

9. A process for preparing novel quinolone derivatives of Formula (IV) comprising stirring optionally protected *cis*-2,8-diazabicyclo[4.3.0]nonane derivatives of formula (V) with the compound of formula (IV-2) in a solvent in the presence of basic, neutral, or acidic alumina:



wherein,

30 X_1 , X_2 , Y_1 , R_1 , R_2 , R_3 , R_4 and A are the same as defined in Claim 3 or R_2 is a protecting group, and thereafter optionally deprotecting and interconverting R_3 and R_4 .

10. A process for preparing novel quinolone derivatives of Formula (IV) comprising following steps:


35

- 36 -

(1) activating the *cis*-isomer of a compound of formula (I) with an activating agent such as carbodiimidazole in the presence of a solvent such as chloroform, tetrahydrofuran; and


5 (2) stirring the mixture of step (1) together with solution prepared by treating nitromethane, diethylmalonate, dimethylmalonate, ethylnitrylacetae with a base such as sodium hydride, calcium carbonate, sodium carbonate in the presence of a solvent such as tetrahydrofuran, and the like:

10




15

(V)



(VI-1)




(IV)

20 wherein,

X₁, X₂, Y₁, R₁, R₂, R₃, R₄, and A are the same as defined in Claim 3 and thereafter optionally deprotecting and interconverting R₃ and R₄.

11. Novel *trans*-2,8-diazabicyclo[4.3.0]nonane derivatives of formula (II):

25



30







(II)

wherein,

35 Y₁, Y₂, and R₂ are the same as defined in Claim 1.

12. A process for preparing novel *trans*-2,8-diazabicyclo[4.3.0]nonane derivatives of formula (II) comprising the following steps:

- (1) reacting compound of formula (VII) or an alternative N-protected form with β -alanine derivatives of formula (XI) in the presence of ethanol to give compound of formula (VIII);
- (2) cyclizing the compound of formula (VIII) with base for example alkoxide such as sodium ethoxide or potassium *t*-butoxide to give compound of formula (IX);
- (3) reducing the carbonyl group in compound of formula (IX) to a methylene group e.g. tosylhydrazine in a solvent of ethanol or methanol to obtain tosylhydrazone and then, by reducing the resulting compound with sodium cyanoborohydride to give compound of formula (X); and
- (4) deprotecting the compound of formula (X) for example in a solvent such as methanol in the presence of a catalyst such as palladium or platinum;



- 38 -


wherein,

Y_1 , Y_2 , and R_2 are the same as defined in Claim 1.

13. A process for preparing novel *trans*-2,8-diazabicyclo[4.3.0]nonane derivatives
5 of formula (II) comprising the following steps:

- (1) reacting compound of formula (XII) or alternative protected form with
β-alanine derivatives of formula (XI) to give *trans* isomer of formula
(XIII);
10
- (2) converting the resulting hydroxy group to carboxy ester e.g. by
 - (a) reacting *trans* isomer of formula (XIII) with methansulfonyl
15 chloride and lithium chloride in a solvent such as methylene chloride
or chloroform in the presence of an organic base such as triethylamine
or diisopropylethylamine to give *cis* isomer of formula (XIV);
 - (b) reacting *cis* isomer of formula (XIV) with potassium cyanate
20 or sodium cyanate in a solvent to give *trans* isomer of formula (XV);
- (3) cyclizing the compound of formula (XVI) for example with alkoxide
such as sodium ethoxide or potassium *t*-butoxide at room temperature
in the aromatic solvent such as benzene, toluene to give compound of
25 formula (IX);
- (4) reducing the compound of formula (IX) for example with zinc amalgam
in the presence of hydrochloric acid to give compound of formula (X);
and
30
- (5) deprotecting the compound of formula (X) in a solvent such as
methanol in the presence of a catalyst such as palladium or platinum;

- 39 -



wherein,

Y_1 , Y_2 and R_2 are the same as defined above.


25

14. A process for preparing *cis*-2,8-diazabicyclo[4.3.0]nonane derivatives of the formula (V) comprising the following steps:


- 30
- (1) suspending pyridine derivatives of formula (XVII) in a solvent such as methanol and adding thionylchloride thereto and then stirring the resulting compound under reflux to give the corresponding ester compound such as of formula (XVIII);
 - 35
 - (2) reducing the compound of formula (XVIII) in a solvent such as ethylether or THF to give alcohols of formula (XIX);

- 40 -


- (3) chlorinating, brominating, or methane sulfonylating alcohols of formula (XIX) to give compound of formula (XX);
- (4) cyclising the compound of formula (XX) for example with tosylimide and sodium hydride in a solvent such as DMF to give cyclized compound of formula (XXI);
- (5) hydrolyzing the compound of formula (XXI) for example with 48% of hydrobromic acid to give amines of formula (XXII);
- (6) reacting amine compounds of formula (XXII) with R_2I such as methane iodide and acid anhydrous in a suitable solvent such as methylene chloride or ethyl alcohol to give salts of pyridine of formula (XXIII); and
- (7) hydrogenating the compound of formula (XXIII) in a suitable solvent such as methanol or ethanol in the presence of a catalyst such as palladium or platinum;




(XVII)




(XVIII)




(XVIII)



(XX)




(XXI)




(XXII)

5



(XXIII)



(V)

10

wherein,

X_3 represents chloro, bromo, or methanesulfonyloxy group; and Y_1 and R_2 are the same as defined in Claim 1.

15 15. A pharmaceutical composition which contains a compound or pharmaceutically acceptable salts of: Formula (I) according to Claim 1; Formula (III) according to Claim 3; or Formula (IV) according to Claim 5, as an active ingredient in an effective amount.

20 16. A compound or pharmaceutically acceptable salts of: Formula (I) according to Claim 1; Formula (III) according to Claim 3; or Formula (IV) according to Claim 5, for use as an antibacterial agent in a method for therapeutic treatment of the human or animal body.

25 17. A method for the treatment of bacterial infection characterized in that a pharmaceutical composition according to Claim 12 is administered to a host in the need of such treatment in the therapeutically effective amount.

30 18. Use of a compound or pharmaceutically acceptable salts of: Formula (I) according to Claim 1; Formula (III) according to Claim 3; or Formula (IV) according to Claim 5, for the preparation of an antibacterial medicament.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 94/00005

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁵: C 07 D 487/18, 519/00, 471/04; A 61 K 31/47, 31/435, 31/445

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁵: C 07 D 487/00, 519/00, 471/00, 215/00; A 61 K 31/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

AT

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP, A2, 0 266 576 (BRISTOL-MYERS COMPANY) 11 May 1988 (11.05.88), claims 1-6, 21-23; abstract; page 15, lines 25-53.	1,3,15-18
A	DE, A1, 3 514 076 (TOYAMA CHEMICAL CO.LTD.) 31 October 1985 (31.10.85), claims 1,2,7,38-39,49.	1,3,15-18
A	DE, A1, 3 632 222 (BAYER AG) 07 April 1988 (07.04.88), abstract; claim 1.	1,15-18
A	DE, A1, 4 032 560 (BAYER AG) 16 April 1992 (16.04.92), claims 1-3, 7-10.	1,3,15-18
A	US, A, 5 140 033 (M. SCHRIEWER ET AL.) 18 August 1992 (18.08.92), columns 1-8; column 25, lines 6-9; columns 27, 28,37,38; examples 1,3,6,7.	1,3,11,15-18
A	EP, A1, 0 393 400 (WAKANUGA SEIYAKU KABUSHIKI KAISHA) 24 October 1990 (24.10.90), claims 1,13,18; page 4, lines 15-17; page 5, formula (m).	1,3,11,15-18
A	DE, A1, 3 906 365 (BAYER AG) 18 January 1990 (18.01.90), abstract; claims 1-4,8,9; examples 13-15, 22-25, 31-33, 49-51,53; page 6, lines 36-53; page 17, lines 25-28.	1,3,11,15-18

☐ Further documents are listed in the continuation of Box C.
 ☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

08 March 1994 (08.03.94)

Date of mailing of the international search report

04 May 1994 (04.05.94)

 Name and mailing address of the ISA/AT
 AUSTRIAN PATENT OFFICE
 Kohlmarkt 8-10
 A-1014 Vienna
 Facsimile No. 1/53424/535

Authorized officer

Mazzucco e.h.

Telephone No. 1/5337058/33

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 94/00005

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 17 (please see remark)
because they relate to subject matter not required to be searched by this Authority, namely:

Remark:
Although claim 17 is directed to a method of treatment of the human or animal body by therapy the search has been carried out and based on the alleged effects of the composition (Rule 39.1(iv) PCT). The relevant documents are listed in the search report.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/KR 94/00005

Im Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
EP A2 266576	11-05-88	CN A 87106925	14-09-88
		CS A2 8707295	14-11-89
		CS B2 270597	12-07-90
		EP A3 266576	22-03-89
		IL A0 84105	31-03-88
		IL A0 102173	14-01-93
		IL A0 102174	14-01-93
		NZ A 222047	29-01-91
		PL A1 268098	01-09-88
		PL B1 154473	30-08-91
		PL B1 156484	31-03-92
		PT A 85886	01-11-87
		PT B 85886	31-07-90
		YU A 1310/88	31-12-88
		YU A 1868/87	31-12-88
		US A 4954507	04-09-90
		US A 4965273	23-10-90
		AU A1 81581/87	06-05-88
		AU B2 611400	13-06-91
		AU A1 76326/91	08-08-91
		CS A2 8807400	14-11-89
		CS B2 270598	12-07-90
		DD A5 266354	29-03-89
		DD A5 280530	11-07-90
		DK A0 3555/88	28-06-88
		DK A 3555/88	23-08-88
		EG A 18484	30-04-93
		EP A1 288519	02-11-88
		EP A4 288519	15-04-92
		FI A 883894	23-08-88
		FI A0 883894	23-08-88
		HU A2 52500	28-07-90
		HU B 203753	30-09-91
		HU A0 911136	28-10-91
		NO A0 883077	08-07-88
		NO A 883077	22-08-88
		ZA A 8707471	25-05-88
		WO A1 8802627	21-04-88
DE A1 3514076	31-10-85	AT A 1224/85	15-06-89
		AT A 2678/88	15-09-89
		AT B 389698	10-01-90
		AT B 390258	10-04-90
		AU A1 41650/85	31-10-85
		AU B2 565087	03-09-87
		AU A1 81804/87	24-03-88
		AU B2 612993	25-07-91
		BE A1 902279	25-10-85
		CH A 673458	15-03-90
		CS B2 250684	14-05-87
		CS B2 250698	14-05-87
		DD A5 238795	03-09-86
		DE C2 3514076	30-03-89
		DE C2 3546658	02-04-92
		DK A0 1856/85	25-04-85
		DK A 1856/85	27-10-85
		DK B 165877	01-02-93
		DK C 165877	21-06-93
		EG A 17339	30-06-89
		ES A1 542584	16-09-86
		ES A5 542584	16-10-86
		ES A1 8700256	01-01-87
		ES A1 551538	01-07-87
		ES A5 551538	30-07-87

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/KR 94/00005

ES A1	8706673	16-09-87
FI A0	851637	25-04-85
FI A	851637	27-10-85
FI B	80453	28-02-90
FI C	80453	11-06-90
FR A1	2563521	31-10-85
FR A1	2614620	04-11-88
FR B1	2563521	03-02-89
FR B1	2614620	09-03-90
GB A0	8510297	30-05-85
GB A1	2158825	20-11-85
GB A0	8716897	26-08-87
GB A1	2191776	23-12-87
GB B2	2158825	28-01-89
GB B2	2191776	28-03-90
HU A2	38634	30-06-86
HU B	194226	28-01-88
HU B	197571	28-04-89
IL A0	75021	30-08-85
IT A0	8548002	26-04-85
IT A	1209953	30-08-89
JP A2	60228479	13-11-85
JP B4	63020828	30-04-88
KR B1	8701693	24-09-87
LU A	85871	16-12-85
NL A	8501172	18-11-85
NL B	187314	18-03-91
NL A	9100647	01-08-91
NL A	9100648	01-08-91
NL C	187314	16-08-91
NO A	851643	28-10-85
NO B	162238	21-08-89
NO C	162238	06-12-89
NZ A	211895	28-07-88
PH A	22801	12-12-88
PH A	25046	28-01-91
PH A	25228	27-03-91
PL A1	253108	17-12-85
PL B1	147392	31-05-89
PT A	80349	01-05-85
PT B	80349	30-09-87
RO B3	91871	30-07-87
RO B3	95509	30-09-88
SE A0	8502017	25-04-85
SE A	8502017	27-10-85
SE A	8804586	20-12-88
SE A0	8804586	20-12-88
SE B	463102	08-10-90
SE C	463102	07-02-91
ZA A	8503102	30-12-86
JP A2	63132888	04-06-88

DE A1 3632222 07-04-88 keine - none - rien

DE A1	4032560	16-04-92	EP A1	481274	22-04-92
			JP A2	4282384	07-10-92
			US A	5202337	13-04-93
			US A	5284855	08-02-94

US A	5140033	18-08-92	AU A1	52317/90	04-10-90
			AU B2	638005	17-06-93
			CA AA	2013449	03-10-90
			CN A	1046162	17-10-90
			DD A5	298400	20-02-92
			DE A1	3910663	04-10-90
			EP A1	391132	10-10-90
			FI A0	901615	30-03-90
			HU A0	902055	28-08-90
			HU A2	56563	30-09-91
			HU A0	912263	30-12-91
			HU A2	58056	28-01-92
			HU B	204811	28-02-92
			IL A0	93954	23-12-90
			JP A2	2289583	29-11-90
			NO A0	901274	20-03-90

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/KR 94/00005

			NO A	901274	04-10-90
			NO B	173547	20-09-93
			NZ A	233142	25-09-92
			PT A	93639	20-11-90
			US A	5252734	12-10-93
			ZA A	9002510	30-01-91
<hr/>					
EP A1	393400	24-10-90	AU A1	52281/90	04-10-90
			AU B2	623757	21-05-92
			CA AA	2012681	30-09-90
			CN A	1045971	10-10-90
			HU A0	902023	28-07-90
			HU A2	58315	28-02-92
			IL A0	93938	23-12-90
<hr/>					
			PT A	93599	20-11-90
			US A	5245037	14-09-93
			JP A2	3188074	16-08-91
			ZA A	9002483	27-11-91
<hr/>					
DE A1	3906365		PT A	91165	08-02-90
			AU A1	36594/89	15-03-90
			AU B2	616277	24-10-91
			AU A1	10283/92	27-02-92
			AU A1	25286/92	26-11-92
			CN A	1039589	14-02-90
			DK A0	3500/89	14-07-89
			DK A	3500/89	16-01-90
			EP A2	350733	17-01-90
			EP A3	350733	27-12-90
			FI A0	893403	13-07-89
			FI A	893403	16-01-90
			HU A2	52087	28-06-90
			HU A0	9301002	28-06-93
			HU B	208130	30-08-93
			IL A0	90940	09-02-90
			JP A2	2069474	08-03-90
			NO A0	892715	29-06-89
			NO A	892715	16-01-90
			NO B	168889	06-01-92
			NO C	168889	15-04-92
			NZ A	229914	26-03-92
			NZ A	239485	26-03-92
			US A	4990517	05-02-91
			US A	5059597	22-10-91